NO20010479L - Tricykliske sulfonamider og deres derivater som inhibitorer av matriksmetalloproteinaser - Google Patents

Tricykliske sulfonamider og deres derivater som inhibitorer av matriksmetalloproteinaser

Info

Publication number
NO20010479L
NO20010479L NO20010479A NO20010479A NO20010479L NO 20010479 L NO20010479 L NO 20010479L NO 20010479 A NO20010479 A NO 20010479A NO 20010479 A NO20010479 A NO 20010479A NO 20010479 L NO20010479 L NO 20010479L
Authority
NO
Norway
Prior art keywords
inhibitors
derivatives
matrix metalloproteinases
tricyclic sulfonamides
sulfonamides
Prior art date
Application number
NO20010479A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010479D0 (no
Inventor
Patrick Michael O'brien
Joseph Armand Picard
Drago Robert Sliskovic
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20010479L publication Critical patent/NO20010479L/no
Publication of NO20010479D0 publication Critical patent/NO20010479D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/28—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/28—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal
    • H04M15/30—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal the meter or calculation of charges not being controlled from an exchange
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/31—Distributed metering or calculation of charges
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/49—Connection to several service providers
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/80—Rating or billing plans; Tariff determination aspects
    • H04M15/8044—Least cost routing
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/83—Notification aspects
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/01—Details of billing arrangements
    • H04M2215/0168—On line or real-time flexible customization or negotiation according to wishes of subscriber
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/42—Least cost routing, i.e. provision for selecting the lowest cost tariff
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/46—Connection to several service providers
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/74—Rating aspects, e.g. rating parameters or tariff determination apects
    • H04M2215/745—Least cost routing, e.g. Automatic or manual, call by call or by preselection
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/82—Advice-of-Charge [AOC], i.e. notify subscriber of charges/cumulative charge; meter at the substation
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/92—Autonomous calculations of charges in terminal, i.e. meter not controlled from exchange
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/96—Distributed calculation of charges, e.g. in different nodes like for mobiles between HLR and VLR, or between the terminal and the billing function

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
NO20010479A 1998-07-30 2001-01-29 Tricykliske sulfonamider og deres derivater som inhibitorer av matriksmetalloproteinaser NO20010479D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9500698P 1998-07-30 1998-07-30
PCT/US1999/012273 WO2000006561A1 (en) 1998-07-30 1999-06-02 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases

Publications (2)

Publication Number Publication Date
NO20010479L true NO20010479L (no) 2001-01-29
NO20010479D0 NO20010479D0 (no) 2001-01-29

Family

ID=22248526

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010479A NO20010479D0 (no) 1998-07-30 2001-01-29 Tricykliske sulfonamider og deres derivater som inhibitorer av matriksmetalloproteinaser

Country Status (32)

Country Link
US (2) US6420408B1 (id)
EP (1) EP1100792B1 (id)
JP (1) JP2002521478A (id)
KR (1) KR20010072089A (id)
CN (1) CN1310716A (id)
AP (1) AP2001002037A0 (id)
AT (1) ATE261954T1 (id)
AU (1) AU758619B2 (id)
BG (1) BG105185A (id)
BR (1) BR9912600A (id)
CA (1) CA2335077A1 (id)
DE (1) DE69915634T2 (id)
DK (1) DK1100792T3 (id)
EA (1) EA200100158A1 (id)
EE (1) EE200100063A (id)
ES (1) ES2216614T3 (id)
GE (1) GEP20033052B (id)
HR (1) HRP20010078A2 (id)
HU (1) HUP0102714A3 (id)
ID (1) ID27192A (id)
IL (1) IL140746A0 (id)
IS (1) IS5810A (id)
NO (1) NO20010479D0 (id)
NZ (1) NZ509439A (id)
OA (1) OA11589A (id)
PL (1) PL345776A1 (id)
PT (1) PT1100792E (id)
SK (1) SK1192001A3 (id)
TR (1) TR200100239T2 (id)
WO (1) WO2000006561A1 (id)
YU (1) YU6701A (id)
ZA (1) ZA200100455B (id)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
MXPA01013171A (es) 2001-02-14 2004-05-21 Warner Lambert Co Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz.
AR034390A1 (es) * 2001-08-03 2004-02-25 Schering Corp Derivados de 1-sulfonil-tetrahidro quinolinas sustituidas, composiciones farmaceuticas y el uso de las mismas para la elaboracion de medicamentos como inhibidores de la gama secretasa
WO2003032974A2 (en) * 2001-10-12 2003-04-24 Eli Lilly And Company Use of sulfonamide derivatives as pharmaceuticals compounds
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
CA2471099C (en) * 2001-12-20 2011-04-12 Bristol-Myers Squibb Company .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors
KR20050010882A (ko) * 2002-06-11 2005-01-28 와이어쓰 베타 아밀로이드 생산의 치환 페닐술폰아미드 저해제
AU2003281169A1 (en) * 2002-07-17 2004-02-02 Warner-Lambert Company Llc Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
US20050095267A1 (en) * 2002-12-04 2005-05-05 Todd Campbell Nanoparticle-based controlled release polymer coatings for medical implants
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
ATE517926T1 (de) 2003-04-04 2011-08-15 Yeda Res & Dev Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
US8088737B2 (en) 2003-04-04 2012-01-03 Incyte Corporation Compositions, methods and kits relating to Her-2 cleavage
WO2005061448A1 (en) * 2003-12-24 2005-07-07 Monash University Compositions and methods for treating vascular conditions
US20060112494A1 (en) * 2004-12-01 2006-06-01 David Oppong Method of protecting an animal skin product from metalloproteinase activity
CN101702906B (zh) 2007-02-23 2014-02-12 耶达研究及发展有限公司 用于抑制金属蛋白活性的抗体和含有所述抗体的药物组合物
US8012947B2 (en) * 2007-03-15 2011-09-06 Hospital For Special Surgery Methods and compositions for promoting wound healing
US20090285840A1 (en) * 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
CA2676946A1 (en) 2009-08-28 2011-02-28 Lucie Peduto Adam12 inhibitors and their use against inflammation-induced fibrosis
AU2011306398A1 (en) 2010-09-24 2013-05-02 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
US11780934B2 (en) 2016-02-05 2023-10-10 Institut Pasteur Use of inhibitors of ADAM12 as adjuvants in tumor therapies
CN114981251B (zh) * 2020-01-21 2023-11-21 深圳信立泰药业股份有限公司 一种二苯并呋喃类衍生物组织蛋白酶k抑制剂及其制备方法和医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH517068A (de) * 1969-07-09 1971-12-31 Ciba Geigy Ag Verfahren zur Herstellung von neuen Aryloxy- und Arylthioessigsäurederivaten
CH531501A (de) * 1970-03-20 1972-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Aryloxy- und Arylthioalkansäuren, ihren Salzen und funktionellen Derivaten
PH31294A (en) * 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
EP0828726B1 (en) 1995-06-02 2001-10-04 Warner-Lambert Company Tricyclic inhibitors of matrix metalloproteinases
US5883940A (en) 1996-07-01 1999-03-16 Teledynamics Group, Inc. Interactive method and apparatus for the generation of leads
ES2231879T3 (es) 1996-08-16 2005-05-16 Warner-Lambert Company Llc Inhibidores de metaloproteinasas de la matriz de acido butirico.
AU735013B2 (en) * 1996-09-04 2001-06-28 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses
JP2002514180A (ja) * 1996-09-04 2002-05-14 ワーナー―ランバート・コンパニー マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法
HUP0000641A3 (en) * 1996-10-16 2001-02-28 American Cyanamid Company Madi Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
NZ509439A (en) 2002-10-25
YU6701A (sh) 2003-12-31
DK1100792T3 (da) 2004-07-05
WO2000006561A1 (en) 2000-02-10
DE69915634T2 (de) 2004-08-12
IS5810A (is) 2001-01-12
ZA200100455B (en) 2002-01-16
ES2216614T3 (es) 2004-10-16
ID27192A (id) 2001-03-08
JP2002521478A (ja) 2002-07-16
US6492422B2 (en) 2002-12-10
SK1192001A3 (en) 2002-02-05
CA2335077A1 (en) 2000-02-10
KR20010072089A (ko) 2001-07-31
BG105185A (en) 2002-04-30
HUP0102714A3 (en) 2003-01-28
US20020169164A1 (en) 2002-11-14
GEP20033052B (en) 2003-08-25
AU758619B2 (en) 2003-03-27
IL140746A0 (en) 2002-02-10
TR200100239T2 (tr) 2001-05-21
CN1310716A (zh) 2001-08-29
HRP20010078A2 (en) 2002-02-28
PT1100792E (pt) 2004-08-31
EP1100792B1 (en) 2004-03-17
AP2001002037A0 (en) 2001-03-31
NO20010479D0 (no) 2001-01-29
US6420408B1 (en) 2002-07-16
BR9912600A (pt) 2001-05-02
EA200100158A1 (ru) 2001-08-27
ATE261954T1 (de) 2004-04-15
PL345776A1 (en) 2002-01-02
HUP0102714A2 (hu) 2002-01-28
EP1100792A1 (en) 2001-05-23
EE200100063A (et) 2002-06-17
AU4329299A (en) 2000-02-21
OA11589A (en) 2004-07-30
DE69915634D1 (de) 2004-04-22

Similar Documents

Publication Publication Date Title
NO20010479L (no) Tricykliske sulfonamider og deres derivater som inhibitorer av matriksmetalloproteinaser
NO20005265D0 (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
NO996313D0 (no) Nye amidinoderivater og deres anvendelse som trombininhibitorer
DK1133477T3 (da) Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
NO20014409D0 (no) Dimere forbindelser og deres anvendelse som inhibitorer av neuraminidase
NO991922D0 (no) Heteroarylsuccinamider og deres anvendelse som metalloproteinaseinhibitorer
NO986180D0 (no) Nye amidinoderivater og deres anvendelse som trombininhibitorer
NO983074D0 (no) Karbamoyloksyderivater av mutilin og deres anvendelse som antibakterielle midler
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
NO20000294L (no) Derivater av acylpiperazinylpyrimidiner, deres fremstilling og anvendelse som legemidler
DK0989121T3 (da) Substituerede benzamider og deres anvendelse som immunmodulatorer
DK0910573T3 (da) Nye aminosyrederivater og deres anvendelse som thrombininhibitorer
DK1150996T3 (da) Nye amidinobenzylaminderivater og deres anvendelse som thrombin-inhibitorer
DK0602028T3 (da) Aromatiske sulfonamidderivater, deres anvendelse som enzyminhibitorer og farmaceutiske præparater me d indhold deraf
NO20023956D0 (no) Priperidin- og piperazinsubstituerte N-hydroksyformamider som inhibitorer av metalloproteinaser
NO20022007D0 (no) Krystaller av et oksyiminoalkansyrederivater og deres anvendelse som antidiabetika
DK1214302T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
NO20005301D0 (no) Pyrrolidiner som inhibitorer av neuraminidaser
DK1299365T3 (da) 2-aminothiazolinderivater og deres anvendelse som inhibitorer for NO-synthase
NO20013669L (no) Reverse hydroksamatinhibitorer av matriks metalloproteinaser
NO20003199D0 (no) Benzo(C)kinolizinderivater og deres anvendelse som 5- <alfa>reduktaseinhibitorer
EP1222308A4 (en) INHIBITORS OF HISTONE ACETYL ANTIPROTOZOA TRANSFERASE
DK0920330T3 (da) hCG og derivater som inhibitorer af matrixmetalloproteaser
NO20011654L (no) Benzamidderivater som trombininhibitorer
SI1100792T1 (en) Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application